BioSpace News Archive

GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) (“GHG” or the “Company”) is pleased to announce the addition of Mathieu Couillard and the continuing engagement of Twilight Capital on its Advisory Board.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved AUSTEDO XR extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease.

Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. has received accelerated approval from the U.S. Food and Drug Administration for FILSPARI™ to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g.

Pfizer Inc. and Valneva SE announce that Pfizer, as the study sponsor, has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists Phase 3 clinical study.

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced that all of the prefunded warrants that were issued in its public offering that closed on January 11, 2023 have been exercised in full.

BridgeBio Pharma, Inc. announced that on February 13, 2023, the compensation committee of BridgeBio’s board of directors granted 11 new employees restricted stock units for an aggregate of 59,800 shares of the Company’s common stock.

Varian, a Siemens Healthineers company, has entered into an agreement with Nova Scotia Health to lead the digital transformation of the health system’s comprehensive oncology service line.

Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that it is set to join the MSCI USA Small Cap Index according to the list of additions posted by MSCI on February 9, 2023.

Covalon Technologies Ltd., an advanced medical technologies company, will release its Q1 Fiscal 2023 financial results on Thursday, February 23, 2023, before markets open.